Sensus Drug Development Corp., Pharmacia deal

PHA exercised its option to acquire the 81.1 percent of Sensus it did not already own. Last month, Sensus submitted an NDA for its Somavert pegvisomant growth hormone receptor to treat acromegaly. Th...